Argenx’s Phase 3 myositis subgroup readout was complemented by broader immunotherapy R&D that increasingly emphasizes more targeted engineering and delivery constraints. In another preclinical direction, researchers reported albumin-fused antibody design strategies aimed at reducing fetal exposure during pregnancy by exploiting placental transport biology and minimizing IgG transfer. The albumin concept builds on how the neonatal Fc receptor (FcRn) handles IgG and albumin in the placenta, offering a protein-engineering lever for biologic delivery decisions in reproductive-age patients. For therapeutic developers, these updates reinforce an ongoing theme: precision immunology is expanding beyond target selection into pharmacokinetic and tissue-transfer engineering to manage safety tradeoffs.